关注
Johanna A. Kremer Hovinga
Johanna A. Kremer Hovinga
Department of Hematology and Central Hematology Laboratory Inselspital, Bern University Hospital
在 insel.ch 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura
M Scully, SR Cataland, F Peyvandi, P Coppo, P Knöbl, ...
New England Journal of Medicine 380 (4), 335-346, 2019
7862019
Survival and relapse in patients with thrombotic thrombocytopenic purpura
JAK Hovinga, SK Vesely, DR Terrell, B Lämmle, JN George
Blood, The Journal of the American Society of Hematology 115 (8), 1500-1511, 2010
6662010
Caplacizumab for acquired thrombotic thrombocytopenic purpura
F Peyvandi, M Scully, JA Kremer Hovinga, S Cataland, P Knöbl, H Wu, ...
New England Journal of Medicine 374 (6), 511-522, 2016
6122016
Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies
M Scully, S Cataland, P Coppo, J De La Rubia, KD Friedman, JK Hovinga, ...
Journal of thrombosis and haemostasis 15 (2), 312-322, 2017
4332017
The incidence of thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS‐13 deficiency
DR Terrell, LA Williams, SK Vesely, B Lämmle, JAK Hovinga, JN George
Journal of Thrombosis and Haemostasis 3 (7), 1432-1436, 2005
4152005
Thrombotic thrombocytopenic purpura
JA Kremer Hovinga, P Coppo, B Lämmle, JL Moake, T Miyata, ...
Nature reviews Disease primers 3 (1), 1-17, 2017
3552017
ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases
M Rieger, PM Mannucci, JAK Hovinga, A Herzog, G Gerstenbauer, ...
Blood 106 (4), 1262-1267, 2005
3512005
Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies
TA Fuchs, JA Kremer Hovinga, D Schatzberg, DD Wagner, B Lämmle
Blood, The Journal of the American Society of Hematology 120 (6), 1157-1164, 2012
3042012
Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015
EE Page, JA Kremer Hovinga, DR Terrell, SK Vesely, JN George
Blood advances 1 (10), 590-600, 2017
2742017
Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features
JA Reese, DS Muthurajah, JAK Hovinga, SK Vesely, DR Terrell, ...
Pediatric blood & cancer 60 (10), 1676-1682, 2013
2692013
Thrombotic thrombocytopenic purpura
B Lämmle, JAK Hovinga, L Alberio
Journal of Thrombosis and Haemostasis 3 (8), 1663-1675, 2005
2572005
Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura
M Scully, P Knöbl, K Kentouche, L Rice, J Windyga, R Schneppenheim, ...
Blood, The Journal of the American Society of Hematology 130 (19), 2055-2063, 2017
2522017
IgG subclass distribution of anti‐ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura
S Ferrari, GC Mudde, M Rieger, A Veyradier, JAK Hovinga, F Scheiflinger
Journal of Thrombosis and Haemostasis 7 (10), 1703-1710, 2009
2092009
Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura
CC Deford, JA Reese, LH Schwartz, JJ Perdue, JA Kremer Hovinga, ...
Blood, The Journal of the American Society of Hematology 122 (12), 2023-2029, 2013
2042013
ADAMTS‐13, von Willebrand factor and related parameters in severe sepsis and septic shock
JAK Hovinga, S Zeerleder, P Kessler, TR De Wit, JA Van Mourik, CE Hack, ...
Journal of Thrombosis and Haemostasis 5 (11), 2284-2290, 2007
1962007
Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin
JD Studt, JAK Hovinga, G Antoine, M Hermann, M Rieger, F Scheiflinger, ...
Blood 105 (2), 542-544, 2005
1962005
Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency
S Zeerleder, M Schloesser, M Redondo, WA Wuillemin, W Engel, ...
Thrombosis and haemostasis 82 (10), 1240-1246, 1999
1871999
Recombinant ADAMTS13 normalizes von Willebrand factor‐cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies
B Plaimauer, JAK Hovinga, C Juno, MJ Wolfsegger, S Skalicky, ...
journal of Thrombosis and Haemostasis 9 (5), 936-944, 2011
1802011
Impaired DNase1‐mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies
M Jimenez‐Alcazar, M Napirei, R Panda, EC Köhler, JAK Hovinga, ...
Journal of Thrombosis and Haemostasis 13 (5), 732-742, 2015
1522015
Plasma DNA is elevated in patients with deep vein thrombosis
JA Diaz, TA Fuchs, TO Jackson, JAK Hovinga, B Lämmle, PK Henke, ...
Journal of Vascular Surgery: Venous and Lymphatic Disorders 1 (4), 341-348. e1, 2013
1512013
系统目前无法执行此操作,请稍后再试。
文章 1–20